Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
188.51
272.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Total Current Liabilities
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Current Liabilities
¥2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
26%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Current Liabilities
¥6.9B
|
CAGR 3-Years
37%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Current Liabilities
¥4.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Current Liabilities
¥13.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Total Current Liabilities
¥876.9m
|
CAGR 3-Years
62%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Current Liabilities
¥1.1B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Glance View
Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., nestled in the heart of Fujian Province, China, is a firm steeped in history and tradition, yet thriving in today’s modern pharmaceutical landscape. The company is best known for its signature product, Pientzehuang Pills, a centuries-old traditional Chinese medicine believed to offer hepatoprotective and detoxifying properties. Rooted in ancient formulations, Pientzehuang Pills are celebrated for their efficacy in addressing liver ailments and enhancing overall vitality. This has secured their place as a staple in Chinese households, maintaining cultural resonance while appealing to a broader audience through the global rise in demand for alternative medicine. The firm operates with a delicate balance, integrating traditional Chinese medicine practices with increasingly sophisticated production technologies to ensure quality consistency and scalability. Zhangzhou Pientzehuang leverages its brand heritage and expertise in traditional herbal remedies to drive revenue. The company has adeptly positioned itself within both domestic and international markets, capitalizing on the growing interest in holistic health approaches. By focusing on research and development, the company continues to innovate, expanding its product line to include health supplements and preventive solutions that cater to modern health challenges. Its strategic distribution channels, including hospitals, pharmacies, and online platforms, enable broad market penetration, ensuring robust sales growth. This dual strategy of preserving the traditional while embracing the modern allows the company to keep its legacy relevant in a competitive pharmaceutical industry, thereby securing its stronghold in the market and ensuring sustained financial performance.
See Also
What is Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Total Current Liabilities?
Total Current Liabilities
2.5B
CNY
Based on the financial report for Sep 30, 2024, Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Total Current Liabilities amounts to 2.5B CNY.
What is Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
26%
Over the last year, the Total Current Liabilities growth was 12%. The average annual Total Current Liabilities growth rates for Zhangzhou Pientzehuang Pharmaceutical Co Ltd have been 9% over the past three years , 8% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet
